haematology
Blood cancers

High prices of blood cancer drugs aren’t justified by R&D costs

The high prices of new oncology drugs can’t be explained by R&D costs, with drug sales revenues being 15 times greater than the amount spent on development, a new study shows. While the pharmaceutical industry typically cites costs of up to US$3 billion to bring a new drug to market, a new WHO-backed analysis finds ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic